Unnati Pharmax

SUTENAMO 25mg Capsules
Composition: Sunitinib Malate Capsules 25mg
International Trade Name: Sutent®

SUTENAMO 25 is a high-quality Sunitinib Malate 25mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Sutent®. Manufactured in WHO-GMP certified facilities, SUTENAMO Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Sunitinib Malate is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth and angiogenesis by inhibiting key receptors such as VEGFR, PDGFR, KIT, and FLT3. Through targeted pathway inhibition, SUTENAMO 25mg Capsules effectively reduce cancer cell proliferation and tumor vascularization. SUTENAMO 25mg is primarily indicated for the treatment of metastatic renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) after imatinib failure, and pancreatic neuroendocrine tumors (pNETs).

Sunitinib 25mg capsules, SUTENAMO capsules, Sutent biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

SUTENAMO 25 Sunitinib Malate Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SORANAMO 200mg Tablets
Composition: Sorafenib Tablets 200mg
International Trade Name: Nexavar®

SORANAMO 200 is a high-quality Sorafenib 200mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Nexavar®. Manufactured in WHO-GMP certified facilities, SORANAMO Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in multi-kinase inhibitor therapy for solid tumors.

Sorafenib is a multi-kinase inhibitor that targets RAF kinase, VEGFR, PDGFR, and other key signaling pathways involved in tumor growth, angiogenesis, and metastasis. SORANAMO 200mg Tablets are primarily indicated for the treatment of advanced hepatocellular carcinoma (HCC), differentiated thyroid carcinoma (DTC), and renal cell carcinoma (RCC).

Sorafenib 200mg tablets, SORANAMO tablets, Nexavar® biosimilar, multi-kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

SORANAMO 200 Sorafenib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SUTENT 25mg Capsules
Composition: Sunitinib Malate Capsules 25mg
International Trade Name: Sutent®

SUTENT 25 is a high-quality Sunitinib Malate 25mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Sutent®. Manufactured in WHO-GMP certified facilities, SUTENT Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Sunitinib Malate is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth and angiogenesis by inhibiting key receptors such as VEGFR, PDGFR, KIT, and FLT3. Through targeted pathway inhibition, SUTENT 25mg Capsules effectively reduce cancer cell proliferation and tumor vascularization. SUTENT 25mg is primarily indicated for the treatment of metastatic renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) after imatinib failure, and pancreatic neuroendocrine tumors (pNETs).

Sunitinib 25mg capsules, SUTENT capsules, Sutent biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

SUTENT 25 Sunitinib Malate Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

MITANT 25mg Capsules
Composition: Sunitinib Malate Capsules 25mg
International Trade Name: Sutent®

MITANT 25 is a high-quality Sunitinib Malate 25mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Sutent®. Manufactured in WHO-GMP certified facilities, MITANT Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Sunitinib Malate is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth and angiogenesis by inhibiting key receptors such as VEGFR, PDGFR, KIT, and FLT3. Through targeted pathway inhibition, MITANT 25mg Capsules effectively reduce cancer cell proliferation and tumor vascularization. MITANT 25mg is primarily indicated for the treatment of metastatic renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) after imatinib failure, and pancreatic neuroendocrine tumors (pNETs).

Sunitinib 25mg capsules, MITANT capsules, Sutent biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

MITANT 25 Sunitinib Malate Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

MITANT 12.5mg Capsules
Composition: Sunitinib Malate Capsules 12.5mg
International Trade Name: Sutent®

MITANT 12.5 is a high-quality Sunitinib Malate 12.5mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Sutent®. Manufactured in WHO-GMP certified facilities, MITANT Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Sunitinib Malate is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth and angiogenesis by inhibiting key receptors such as VEGFR, PDGFR, KIT, and FLT3. Through targeted pathway inhibition, MITANT 12.5mg Capsules effectively reduce cancer cell proliferation and tumor vascularization. MITANT 12.5mg is primarily indicated for the treatment of metastatic renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) after imatinib failure, and pancreatic neuroendocrine tumors (pNETs).

Sunitinib 12.5mg capsules, MITANT capsules, Sutent biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

MITANT 12.5 Sunitinib Malate Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

Suninat 50mg Capsules
Composition: Sunitinib Malate Capsules 50mg
International Trade Name: Sutent®

Suninat 50 is a high-quality Sunitinib Malate 50mg Capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Sutent®. Manufactured in WHO-GMP certified facilities, Suninat Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in solid tumors driven by angiogenesis and receptor tyrosine kinase signaling.

Sunitinib malate is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks key receptors involved in tumor growth and angiogenesis, including VEGFR, PDGFR, KIT, and FLT3. By inhibiting these signaling pathways, Suninat 50mg Capsules effectively suppress tumor proliferation and blood vessel formation. Suninat 50mg is primarily indicated for the treatment of metastatic renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) after imatinib failure, and pancreatic neuroendocrine tumors (pNETs).

Sunitinib malate 50mg capsules, Suninat 50 capsules, Sutent biosimilar, tyrosine kinase inhibitor therapy, targeted oncology treatment, anti-angiogenic cancer therapy, oncology oral capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

Suninat 50 Sunitinib Malate Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SUTINAT 12.5 Capsules
Composition: Sunitinib Capsules 12.5mg
International Trade Name: Sutent®

SUTINAT 12.5 is a high-quality Sunitinib 12.5mg capsule, a targeted anticancer therapy internationally recognized under the brand name Sutent®. Manufactured in WHO-GMP certified facilities, SUTINAT Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Sunitinib is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth and angiogenesis by inhibiting receptors such as VEGFR, PDGFR, KIT, and FLT3. SUTINAT 12.5 Capsules are primarily indicated for the treatment of metastatic renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) after imatinib failure, and pancreatic neuroendocrine tumors (pNETs).

Sunitinib 12.5mg capsules, SUTINAT capsules, Sutent biosimilar, tyrosine kinase inhibitor therapy, targeted cancer treatment, oncology oral capsules, anticancer drug manufacturer India, pharmaceutical exporter India.

SUTINAT 12.5 Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SUNITCAP 25mg Capsules
Composition: Sunitinib Malate Capsules 25mg
International Trade Name: Sutent®

SUNITCAP 25 is a high-quality Sunitinib Malate 25mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Sutent®. Manufactured in WHO-GMP certified facilities, SUNITCAP Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Sunitinib Malate is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth and angiogenesis by inhibiting key receptors such as VEGFR, PDGFR, KIT, and FLT3. Through targeted pathway inhibition, SUNITCAP 25mg Capsules effectively reduce cancer cell proliferation and tumor vascularization. SUNITCAP 25mg is primarily indicated for the treatment of metastatic renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) after imatinib failure, and pancreatic neuroendocrine tumors (pNETs).

Sunitinib 25mg capsules, SUNITCAP capsules, Sutent biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

SUNITCAP 25 Sunitinib Malate Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SUTEKAST 50mg Capsules
Composition: Sunitinib Malate Capsules 50mg
International Trade Name: Sutent®

SUTEKAST 50 is a high-quality Sunitinib Malate 50mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Sutent®. Manufactured in WHO-GMP certified facilities, SUTEKAST Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Sunitinib Malate is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth and angiogenesis by inhibiting key receptors such as VEGFR, PDGFR, KIT, and FLT3. Through targeted pathway inhibition, SUTEKAST 50mg Capsules effectively reduce cancer cell proliferation and tumor vascularization. SUTEKAST 50mg is primarily indicated for the treatment of metastatic renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) after imatinib failure, and pancreatic neuroendocrine tumors (pNETs).

Sunitinib 50mg capsules, SUTEKAST capsules, Sutent biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

SUTEKAST 50 Sunitinib Malate Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SUNITCAP 50mg Capsules
Composition: Sunitinib Malate Capsules 50mg
International Trade Name: Sutent®

SUNITCAP 50 is a high-quality Sunitinib Malate 50mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Sutent®. Manufactured in WHO-GMP certified facilities, SUNITCAP Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Sunitinib Malate is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth and angiogenesis by inhibiting key receptors such as VEGFR, PDGFR, KIT, and FLT3. Through targeted pathway inhibition, SUNITCAP 50mg Capsules effectively reduce cancer cell proliferation and tumor vascularization. SUNITCAP 50mg is primarily indicated for the treatment of metastatic renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) after imatinib failure, and pancreatic neuroendocrine tumors (pNETs).

Sunitinib 50mg capsules, SUNITCAP capsules, Sutent biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

SUNITCAP 50 Sunitinib Malate Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SUNITCAP 12.5mg Capsules
Composition: Sunitinib Malate Capsules 12.5mg
International Trade Name: Sutent®

SUNITCAP 12.5 is a high-quality Sunitinib Malate 12.5mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Sutent®. Manufactured in WHO-GMP certified facilities, SUNITCAP Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Sunitinib Malate is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth and angiogenesis by inhibiting key receptors such as VEGFR, PDGFR, KIT, and FLT3. Through targeted pathway inhibition, SUNITCAP 12.5mg Capsules effectively reduce cancer cell proliferation and tumor vascularization. SUNITCAP 12.5mg is primarily indicated for the treatment of metastatic renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) after imatinib failure, and pancreatic neuroendocrine tumors (pNETs).

Sunitinib 12.5mg capsules, SUNITCAP capsules, Sutent biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

SUNITCAP 12.5 Sunitinib Malate Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

LENVAT 10 Tablets
Composition: Lenvatinib Tablets 10mg
International Trade Name: Lenvima®

LENVAT 10 is a high-quality Lenvatinib 10mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Lenvima®. Manufactured in WHO-GMP certified facilities, LENVAT Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Lenvatinib is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks key signaling pathways involved in tumor growth and angiogenesis by inhibiting VEGFR, FGFR, PDGFR, KIT, and RET receptors. Through targeted pathway suppression, LENVAT 10mg Tablets effectively reduce tumor proliferation and vascularization. LENVAT 10mg is primarily indicated for the treatment of differentiated thyroid cancer (DTC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and endometrial carcinoma, either as monotherapy or in combination with other anticancer agents.

Lenvatinib 10mg tablets, LENVAT tablets, Lenvima biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

LENVAT 10 Lenvatinib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

LENVAT 4 Capsules
Composition: Lenvatinib Capsules 4mg
International Trade Name: Lenvima®

LENVAT 4 is a high-quality Lenvatinib 4mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Lenvima®. Manufactured in WHO-GMP certified facilities, LENVAT Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Lenvatinib is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks key signaling pathways involved in tumor growth and angiogenesis by inhibiting VEGFR, FGFR, PDGFR, KIT, and RET receptors. Through targeted pathway suppression, LENVAT 4mg Capsules effectively reduce tumor proliferation and vascularization. LENVAT 4mg is primarily indicated for the treatment of differentiated thyroid cancer (DTC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and endometrial carcinoma, either as monotherapy or in combination with other anticancer agents.

Lenvatinib 4mg capsules, LENVAT capsules, Lenvima biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

LENVAT 4 Lenvatinib Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

LENSHIL 10mg Tablets
Composition: Lenvatinib Tablets 10mg
International Trade Name: Lenvima®

LENSHIL 10 is a high-quality Lenvatinib 10mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Lenvima®. Manufactured in WHO-GMP certified facilities, LENSHIL Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Lenvatinib is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks key signaling pathways involved in tumor growth and angiogenesis by inhibiting VEGFR, FGFR, PDGFR, KIT, and RET receptors. Through targeted pathway suppression, LENSHIL 10mg Tablets effectively reduce tumor proliferation and vascularization. LENSHIL 10mg is primarily indicated for the treatment of differentiated thyroid cancer (DTC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and endometrial carcinoma, either as monotherapy or in combination with other anticancer agents.

Lenvatinib 10mg tablets, LENSHIL tablets, Lenvima biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

LENSHIL 10 Lenvatinib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

LENVA 4mg Capsules
Composition: Lenvatinib Capsules 4mg
International Trade Name: Lenvima®

LENVA 4 is a high-quality Lenvatinib 4mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Lenvima®. Manufactured in WHO-GMP certified facilities, LENVA Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Lenvatinib is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks key signaling pathways involved in tumor growth and angiogenesis by inhibiting VEGFR, FGFR, PDGFR, KIT, and RET receptors. Through targeted pathway suppression, LENVA 4mg Capsules effectively reduce tumor proliferation and vascularization. LENVA 4mg is primarily indicated for the treatment of differentiated thyroid cancer (DTC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and endometrial carcinoma, either as monotherapy or in combination with other anticancer agents.

Lenvatinib 4mg capsules, LENVA capsules, Lenvima biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

LENVA 4 Lenvatinib Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

LENTRIS 4mg Capsules
Composition: Lenvatinib Capsules 4mg
International Trade Name: Lenvima®

LENTRIS 4 is a high-quality Lenvatinib 4mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Lenvima®. Manufactured in WHO-GMP certified facilities, LENTRIS Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Lenvatinib is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks key signaling pathways involved in tumor growth and angiogenesis by inhibiting VEGFR, FGFR, PDGFR, KIT, and RET receptors. Through targeted pathway suppression, LENTRIS 4mg Capsules effectively reduce tumor proliferation and vascularization. LENTRIS 4mg is primarily indicated for the treatment of differentiated thyroid cancer (DTC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and endometrial carcinoma, either as monotherapy or in combination with other anticancer agents.

Lenvatinib 4mg capsules, LENTRIS capsules, Lenvima biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

LENTRIS 4 Lenvatinib Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

LENVAKAST 10mg Tablets
Composition: Lenvatinib Tablets 10mg
International Trade Name: Lenvima®

LENVAKAST 10 is a high-quality Lenvatinib 10mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Lenvima®. Manufactured in WHO-GMP certified facilities, LENVAKAST Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Lenvatinib is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks key signaling pathways involved in tumor growth and angiogenesis by inhibiting VEGFR, FGFR, PDGFR, KIT, and RET receptors. Through targeted pathway suppression, LENVAKAST 10mg Tablets effectively reduce tumor proliferation and vascularization. LENVAKAST 10mg is primarily indicated for the treatment of differentiated thyroid cancer (DTC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and endometrial carcinoma, either as monotherapy or in combination with other anticancer agents.

Lenvatinib 10mg tablets, LENVAKAST tablets, Lenvima biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

LENVAKAST 10 Lenvatinib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

LENSHIL 4mg Capsules
Composition: Lenvatinib Capsules 4mg
International Trade Name: Lenvima®

LENSHIL 4 is a high-quality Lenvatinib 4mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Lenvima®. Manufactured in WHO-GMP certified facilities, LENSHIL Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Lenvatinib is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks key signaling pathways involved in tumor growth and angiogenesis by inhibiting VEGFR, FGFR, PDGFR, KIT, and RET receptors. Through targeted pathway suppression, LENSHIL 4mg Capsules effectively reduce tumor proliferation and vascularization. LENSHIL 4mg is primarily indicated for the treatment of differentiated thyroid cancer (DTC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and endometrial carcinoma, either as monotherapy or in combination with other anticancer agents.

Lenvatinib 4mg capsules, LENSHIL capsules, Lenvima biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

LENSHIL 4 Lenvatinib Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

LENVABUZZ 4mg Capsules
Composition: Lenvatinib Capsules 4mg
International Trade Name: Lenvima®

LENVABUZZ 4 is a high-quality Lenvatinib 4mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Lenvima®. Manufactured in WHO-GMP certified facilities, LENVABUZZ Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Lenvatinib is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks key signaling pathways involved in tumor growth and angiogenesis by inhibiting VEGFR, FGFR, PDGFR, KIT, and RET receptors. Through targeted pathway suppression, LENVABUZZ 4mg Capsules effectively reduce tumor proliferation and vascularization. LENVABUZZ 4mg is primarily indicated for the treatment of differentiated thyroid cancer (DTC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and endometrial carcinoma, either as monotherapy or in combination with other anticancer agents.

Lenvatinib 4mg capsules, LENVABUZZ capsules, Lenvima biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

LENVABUZZ 4 Lenvatinib Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

LENVALIEVA 4mg Capsules
Composition: Lenvatinib Capsules 4mg
International Trade Name: Lenvima®

LENVALIEVA 4 is a high-quality Lenvatinib 4mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Lenvima®. Manufactured in WHO-GMP certified facilities, LENVALIEVA Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Lenvatinib is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks key signaling pathways involved in tumor growth and angiogenesis by inhibiting VEGFR, FGFR, PDGFR, KIT, and RET receptors. Through targeted pathway suppression, LENVALIEVA 4mg Capsules effectively reduce tumor proliferation and vascularization. LENVALIEVA 4mg is primarily indicated for the treatment of differentiated thyroid cancer (DTC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and endometrial carcinoma, either as monotherapy or in combination with other anticancer agents.

Lenvatinib 4mg capsules, LENVALIEVA capsules, Lenvima biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

LENVALIEVA 4 Lenvatinib Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

LENVALIEVA 10mg Capsules
Composition: Lenvatinib Capsules 10mg
International Trade Name: Lenvima®

LENVALIEVA 10 is a high-quality Lenvatinib 10mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Lenvima®. Manufactured in WHO-GMP certified facilities, LENVALIEVA Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Lenvatinib is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks key signaling pathways involved in tumor growth and angiogenesis by inhibiting VEGFR, FGFR, PDGFR, KIT, and RET receptors. Through targeted pathway suppression, LENVALIEVA 10mg Capsules effectively reduce tumor proliferation and vascularization. LENVALIEVA 10mg is primarily indicated for the treatment of differentiated thyroid cancer (DTC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and endometrial carcinoma, either as monotherapy or in combination with other anticancer agents.

Lenvatinib 10mg capsules, LENVALIEVA capsules, Lenvima biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

LENVALIEVA 10 Lenvatinib Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

LENVAKAST 4mg Capsules
Composition: Lenvatinib Capsules 4mg
International Trade Name: Lenvima®

LENVAKAST 4 is a high-quality Lenvatinib 4mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Lenvima®. Manufactured in WHO-GMP certified facilities, LENVAKAST Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Lenvatinib is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks key signaling pathways involved in tumor growth and angiogenesis by inhibiting VEGFR, FGFR, PDGFR, KIT, and RET receptors. Through targeted pathway suppression, LENVAKAST 4mg Capsules effectively reduce tumor proliferation and vascularization. LENVAKAST 4mg is primarily indicated for the treatment of differentiated thyroid cancer (DTC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and endometrial carcinoma, either as monotherapy or in combination with other anticancer agents.

Lenvatinib 4mg capsules, LENVAKAST capsules, Lenvima biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

LENVAKAST 4 Lenvatinib Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

PAZINIB 200 Tablets
Composition: Pazopanib Tablets 200mg
International Trade Name: Votrient®

PAZINIB 200 is a high-quality Pazopanib 200mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Votrient®. Manufactured in WHO-GMP certified facilities, PAZINIB Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Pazopanib is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth and angiogenesis by inhibiting VEGFR, PDGFR, and c-KIT receptors. Through targeted pathway inhibition, PAZINIB 200mg Tablets effectively reduce tumor proliferation and vascularization. PAZINIB 200mg is primarily indicated for the treatment of advanced renal cell carcinoma (RCC) and soft tissue sarcoma (STS) in patients who are not candidates for chemotherapy.

Pazopanib 200mg tablets, PAZINIB tablets, Votrient biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

PAZINIB 200 Pazopanib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

CABONROM 20mg Tablets
Composition: Cabozantinib Tablets 20mg
International Trade Name: Cabometyx®

CABONROM 20 is a high-quality Cabozantinib 20mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Cabometyx®. Manufactured in WHO-GMP certified facilities, CABONROM Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and tyrosine kinase–dependent malignancies.

Cabozantinib is a multi-targeted tyrosine kinase inhibitor (TKI) that inhibits key signaling pathways involved in tumor growth, metastasis, and angiogenesis by targeting MET, VEGFR, AXL, RET, and other receptor kinases. Through targeted pathway suppression, CABONROM 20mg Tablets effectively reduce tumor proliferation, invasion, and tumor vascularization. CABONROM 20mg is primarily indicated for the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and differentiated thyroid cancer (DTC).

Cabozantinib 20mg tablets, CABONROM tablets, Cabometyx biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

CABONROM 20 Cabozantinib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

CAZANAT 60mg Tablets
Composition: Cabozantinib Tablets 60mg
International Trade Name: Cabometyx®, Cometriq®

CAZANAT 60 is a high-quality Cabozantinib 60mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand names Cabometyx® and Cometriq®. Manufactured in WHO-GMP certified facilities, CAZANAT Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in receptor tyrosine kinase–dependent malignancies.

Cabozantinib is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth, metastasis, and angiogenesis by inhibiting key receptors including MET, VEGFR, AXL, and RET. CAZANAT 60mg Tablets effectively reduce tumor proliferation, invasion, and tumor vascularization. CAZANAT 60mg is primarily indicated for the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and medullary thyroid carcinoma (MTC).

Cabozantinib 60mg tablets, CAZANAT tablets, Cabometyx® biosimilar, Cometriq® biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

CAZANAT 60 Cabozantinib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

CAZANAT 20mg Tablets
Composition: Cabozantinib Tablets 20mg
International Trade Name: Cabometyx®, Cometriq®

CAZANAT 20 is a high-quality Cabozantinib 20mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand names Cabometyx® and Cometriq®. Manufactured in WHO-GMP certified facilities, CAZANAT Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in receptor tyrosine kinase–dependent malignancies.

Cabozantinib is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth, metastasis, and angiogenesis by inhibiting key receptors including MET, VEGFR, AXL, and RET. CAZANAT 20mg Tablets effectively reduce tumor proliferation, invasion, and tumor vascularization. CAZANAT 20mg is primarily indicated for the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and medullary thyroid carcinoma (MTC).

Cabozantinib 20mg tablets, CAZANAT tablets, Cabometyx® biosimilar, Cometriq® biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

CAZANAT 20 Cabozantinib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

CABOTRES 40mg Tablets
Composition: Cabozantinib Tablets 40mg
International Trade Name: Cometriq®

CABOTRES 40 is a high-quality Cabozantinib 40mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Cometriq®. Manufactured in WHO-GMP certified facilities, CABOTRES Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in receptor tyrosine kinase–dependent malignancies.

Cabozantinib is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth, metastasis, and angiogenesis by inhibiting key receptors including MET, VEGFR, AXL, and RET. CABOTRES 40mg Tablets effectively reduce tumor proliferation, invasion, and tumor vascularization. CABOTRES 40mg is primarily indicated for the treatment of medullary thyroid carcinoma (MTC), advanced renal cell carcinoma (RCC), and hepatocellular carcinoma (HCC).

Cabozantinib 40mg tablets, CABOTRES tablets, Cometriq® biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

CABOTRES 40 Cabozantinib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SORANIB 200mg Tablets
Composition: Sorafenib Tablets 200mg
International Trade Name: Nexavar®

SORANIB 200 is a high-quality Sorafenib 200mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Nexavar®. Manufactured in WHO-GMP certified facilities, SORANIB Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in kinase-driven and angiogenesis-dependent malignancies.

Sorafenib is a multi-kinase inhibitor that targets tumor cell proliferation and angiogenesis by inhibiting key receptors including VEGFR, PDGFR, RAF kinases, and c-KIT. By suppressing these signaling pathways, SORANIB 200mg Tablets effectively reduce tumor growth and vascularization. SORANIB 200mg is primarily indicated for the treatment of advanced hepatocellular carcinoma (HCC), differentiated thyroid carcinoma (DTC), and renal cell carcinoma (RCC).

Sorafenib 200mg tablets, SORANIB tablets, Nexavar biosimilar, kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

SORANIB 200 Sorafenib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SORALIEVA 200mg Tablets
Composition: Sorafenib Tablets 200mg
International Trade Name: Nexavar®

SORALIEVA 200 is a high-quality Sorafenib 200mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Nexavar®. Manufactured in WHO-GMP certified facilities, SORALIEVA Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in multi-kinase inhibitor therapy for solid tumors.

Sorafenib is a multi-kinase inhibitor that targets RAF kinase, VEGFR, PDGFR, and other key signaling pathways involved in tumor growth, angiogenesis, and metastasis. SORALIEVA 200mg Tablets are primarily indicated for the treatment of advanced hepatocellular carcinoma (HCC), differentiated thyroid carcinoma (DTC), and renal cell carcinoma (RCC).

Sorafenib 200mg tablets, SORALIEVA tablets, Nexavar® biosimilar, multi-kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

SORALIEVA 200 Sorafenib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SORAFEKAST 200mg Tablets
Composition: Sorafenib Tablets 200mg
International Trade Name: Nexavar®

SORAFEKAST 200 is a high-quality Sorafenib 200mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Nexavar®. Manufactured in WHO-GMP certified facilities, SORAFEKAST Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in multi-kinase inhibitor therapy for solid tumors.

Sorafenib is a multi-kinase inhibitor that targets RAF kinase, VEGFR, PDGFR, and other key signaling pathways involved in tumor growth, angiogenesis, and metastasis. SORAFEKAST 200mg Tablets are primarily indicated for the treatment of advanced hepatocellular carcinoma (HCC), differentiated thyroid carcinoma (DTC), and renal cell carcinoma (RCC).

Sorafenib 200mg tablets, SORAFEKAST tablets, Nexavar® biosimilar, multi-kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

SORAFEKAST 200 Sorafenib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SORAFIKAST 200mg Tablets
Composition: Sorafenib Tablets 200mg
International Trade Name: Nexavar®

SORAFIKAST 200 is a high-quality Sorafenib 200mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Nexavar®. Manufactured in WHO-GMP certified facilities, SORAFIKAST Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in multi-kinase inhibitor therapy for solid tumors.

Sorafenib is a multi-kinase inhibitor that targets RAF kinase, VEGFR, PDGFR, and other key signaling pathways involved in tumor growth, angiogenesis, and metastasis. SORAFIKAST 200mg Tablets are primarily indicated for the treatment of advanced hepatocellular carcinoma (HCC), differentiated thyroid carcinoma (DTC), and renal cell carcinoma (RCC).

Sorafenib 200mg tablets, SORAFIKAST tablets, Nexavar® biosimilar, multi-kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

SORAFIKAST 200 Sorafenib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SORANAMA Tablets
Composition: Sorafenib Tablets 200mg
International Trade Name: Nexavar®

SORANAMA is a high-quality Sorafenib 200mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Nexavar®. Manufactured in WHO-GMP certified facilities, SORANAMA Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in multi-kinase inhibitor therapy for solid tumors.

Sorafenib is a multi-kinase inhibitor that targets RAF kinase, VEGFR, PDGFR, and other key signaling pathways involved in tumor growth, angiogenesis, and metastasis. SORANAMA Tablets are primarily indicated for the treatment of advanced hepatocellular carcinoma (HCC), differentiated thyroid carcinoma (DTC), and renal cell carcinoma (RCC).

Sorafenib tablets, SORANAMA tablets, Nexavar® biosimilar, multi-kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

SORANAMA Sorafenib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SORALIEVA 200mg Tablets
Composition: Sorafenib Tablets 200mg
International Trade Name: Nexavar®

SORALIEVA 200 is a high-quality Sorafenib 200mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Nexavar®. Manufactured in WHO-GMP certified facilities, SORALIEVA Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in multi-kinase inhibitor therapy for solid tumors.

Sorafenib is a multi-kinase inhibitor that targets RAF kinase, VEGFR, PDGFR, and other key signaling pathways involved in tumor growth, angiogenesis, and metastasis. SORALIEVA 200mg Tablets are primarily indicated for the treatment of advanced hepatocellular carcinoma (HCC), differentiated thyroid carcinoma (DTC), and renal cell carcinoma (RCC).

Sorafenib 200mg tablets, SORALIEVA tablets, Nexavar® biosimilar, multi-kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

SORALIEVA 200 Sorafenib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SUTENAMO 50mg Capsules
Composition: Sunitinib Malate Capsules 50mg
International Trade Name: Sutent®

SUTENAMO 50 is a high-quality Sunitinib Malate 50mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Sutent®. Manufactured in WHO-GMP certified facilities, SUTENAMO Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven solid tumors.

Sunitinib malate is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth and angiogenesis by inhibiting key receptors such as VEGFR, PDGFR, KIT, and FLT3. Through targeted pathway inhibition, SUTENAMO 50mg Capsules effectively reduce cancer cell proliferation and tumor vascularization. SUTENAMO 50mg is primarily indicated for the treatment of metastatic renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) after imatinib failure, and pancreatic neuroendocrine tumors (pNETs).

Sunitinib malate 50mg capsules, SUTENAMO capsules, Sutent biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

SUTENAMO 50 Sunitinib Malate Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SUNITYRA 12.5mg Capsules
Composition: Sunitinib Malate Capsules 12.5mg
International Trade Name: Sutent®

SUNITYRA 12.5 is a high-quality Sunitinib Malate 12.5mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Sutent®. Manufactured in WHO-GMP certified facilities, SUNITYRA Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Sunitinib malate is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth and angiogenesis by inhibiting key receptors such as VEGFR, PDGFR, KIT, and FLT3. Through targeted pathway inhibition, SUNITYRA 12.5mg Capsules effectively reduce cancer cell proliferation and tumor vascularization. SUNITYRA 12.5mg is primarily indicated for the treatment of metastatic renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) after imatinib failure, and pancreatic neuroendocrine tumors (pNETs).

Sunitinib 12.5mg capsules, SUNITYRA capsules, Sutent biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

SUNITYRA 12.5 Sunitinib Malate Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

LENCED 4mg Capsules
Composition: Lenvatinib Capsules 4mg
International Trade Name: Lenvima®

LENCED 4 is a high-quality Lenvatinib 4mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Lenvima®. Manufactured in WHO-GMP certified facilities, LENCED Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Lenvatinib is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks key signaling pathways involved in tumor growth and angiogenesis by inhibiting VEGFR, FGFR, PDGFR, KIT, and RET receptors. Through targeted pathway suppression, LENCED 4mg Capsules effectively reduce tumor proliferation and vascularization. LENCED 4mg is primarily indicated for the treatment of differentiated thyroid cancer (DTC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and endometrial carcinoma, either as monotherapy or in combination with other anticancer agents.

Lenvatinib 4mg capsules, LENCED capsules, Lenvima biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

LENCED 4 Lenvatinib Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

LENVA 10mg Tablets
Composition: Lenvatinib Tablets 10mg
International Trade Name: Lenvima®

LENVA 10 is a high-quality Lenvatinib 10mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Lenvima®. Manufactured in WHO-GMP certified facilities, LENVA Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Lenvatinib is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks key signaling pathways involved in tumor growth and angiogenesis by inhibiting VEGFR, FGFR, PDGFR, KIT, and RET receptors. Through targeted pathway suppression, LENVA 10mg Tablets effectively reduce tumor proliferation and vascularization. LENVA 10mg is primarily indicated for the treatment of differentiated thyroid cancer (DTC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and endometrial carcinoma, either as monotherapy or in combination with other anticancer agents.

Lenvatinib 10mg tablets, LENVA tablets, Lenvima biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

LENVA 10 Lenvatinib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SORAFENAT Tablets
Composition: Sorafenib Tablets
International Trade Name: Nexavar®

SORAFENAT is a high-quality Sorafenib tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Nexavar®. Manufactured in WHO-GMP certified facilities, SORAFENAT Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in kinase-driven and angiogenesis-dependent malignancies.

Sorafenib is a multi-kinase inhibitor that targets tumor cell proliferation and angiogenesis by inhibiting key receptors including VEGFR, PDGFR, RAF kinases, and c-KIT. By suppressing these signaling pathways, SORAFENAT Tablets effectively reduce tumor growth and vascularization. SORAFENAT is primarily indicated for the treatment of advanced hepatocellular carcinoma (HCC), differentiated thyroid carcinoma (DTC), and renal cell carcinoma (RCC).

Sorafenib tablets, SORAFENAT tablets, Nexavar biosimilar, kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

SORAFENAT Sorafenib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SORABUZZ 200mg Tablets
Composition: Sorafenib Tablets 200mg
International Trade Name: Nexavar®

SORABUZZ 200 is a high-quality Sorafenib 200mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Nexavar®. Manufactured in WHO-GMP certified facilities, SORABUZZ Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in multi-kinase inhibitor therapy for solid tumors.

Sorafenib is a multi-kinase inhibitor that targets RAF kinase, VEGFR, PDGFR, and other key signaling pathways involved in tumor growth, angiogenesis, and metastasis. SORABUZZ 200mg Tablets are primarily indicated for the treatment of advanced hepatocellular carcinoma (HCC), differentiated thyroid carcinoma (DTC), and renal cell carcinoma (RCC).

Sorafenib 200mg tablets, SORABUZZ tablets, Nexavar® biosimilar, multi-kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

SORABUZZ 200 Sorafenib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

CAZANAT 40mg Tablets
Composition: Cabozantinib Tablets 40mg
International Trade Name: Cabometyx®, Cometriq®

CAZANAT 40 is a high-quality Cabozantinib 40mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand names Cabometyx® and Cometriq®. Manufactured in WHO-GMP certified facilities, CAZANAT Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in receptor tyrosine kinase–dependent malignancies.

Cabozantinib is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth, metastasis, and angiogenesis by inhibiting key receptors including MET, VEGFR, AXL, and RET. CAZANAT 40mg Tablets effectively reduce tumor proliferation, invasion, and tumor vascularization. CAZANAT 40mg is primarily indicated for the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and medullary thyroid carcinoma (MTC).

Cabozantinib 40mg tablets, CAZANAT tablets, Cabometyx® biosimilar, Cometriq® biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

CAZANAT 40 Cabozantinib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.